QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.070-2.570 for the period, compared to the consensus EPS estimate of 2.450. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

Analyst Ratings Changes

Several brokerages recently weighed in on QDEL. UBS Group lifted their price target on QuidelOrtho from $43.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday. Royal Bank of Canada reduced their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a research note on Thursday. Jefferies Financial Group assumed coverage on shares of QuidelOrtho in a research note on Tuesday, December 10th. They issued a “hold” rating and a $43.00 price target on the stock. Citigroup upgraded shares of QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. Finally, William Blair reiterated a “market perform” rating on shares of QuidelOrtho in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $52.71.

QuidelOrtho Price Performance

QDEL stock traded up $2.27 during midday trading on Thursday, reaching $42.21. The stock had a trading volume of 929,199 shares, compared to its average volume of 889,807. QuidelOrtho has a 52-week low of $29.74 and a 52-week high of $49.56. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. The company’s fifty day simple moving average is $43.28 and its 200 day simple moving average is $42.35. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -1.51 and a beta of 0.08.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. As a group, sell-side analysts predict that QuidelOrtho will post 1.73 earnings per share for the current fiscal year.

Insider Transactions at QuidelOrtho

In related news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of QuidelOrtho stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Brian J. Blaser bought 6,033 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $41.42 per share, with a total value of $249,886.86. Following the completion of the acquisition, the chief executive officer now owns 6,033 shares in the company, valued at $249,886.86. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.